About HandaPharma

This author has not yet filled in any details.
So far HandaPharma has created 26 blog entries.

Handa Pharmaceuticals Announces TruPharma’s U.S. Launch Of Its FDA-Approved ANDA for Lamotrigine Extended Release Tablets

Tainan City, Taiwan, June 6, 2017 — Handa Pharmaceuticals, Inc. (Taiwan Exchange: 6620) (together with its wholly owned U.S. subsidiary, Handa Pharmaceuticals, LLC, “Handa”), a specialty pharmaceutical company focusing on the research, development and commercialization of innovative prescription brand and high-barrier generic drug products, announced today that TruPharma, LLC (“TruPharma”) has started to market and [...]

June 6th, 2017|News|

Handa Pharmaceuticals, Inc. Announces FDA Approval for Generic Version of AstraZeneca’s SEROQUEL XR® Extended Release Tablets

Tainan City, Taiwan, May 10, 2017 — Handa Pharmaceuticals, Inc. (Taiwan Exchange: 6620) (“Handa”), a specialty pharmaceutical company focusing on the research, development and commercialization of innovative prescription brand and high-barrier generic drug products, announced that its partner, Par Pharmaceutical, Inc. an Endo International company (“Par”), received final approval from the U.S. Food and Drug [...]

May 10th, 2017|News|

Handa Pharmaceuticals Announces Endo Begins Shipping Generic Version of AstraZeneca’s SEROQUEL XR®

TAINAN TAIWAN, November 1, 2016 – Handa Pharmaceuticals, Inc. (“Handa”), a specialty pharmaceutical company based in Tainan, Taiwan, announced today that Par Pharmaceutical, Inc. (“Par”), an operating company of Endo International plc (NASDAQ: ENDP) (TSX: ENL) has begun shipping four dosage strengths (50 mg, 150 mg, 200 mg and 300 mg) of quetiapine fumarate extended [...]

November 1st, 2016|News|